GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Net Policyholder Benefits/Claims

Cambium Bio (ASX:CMB) Net Policyholder Benefits/Claims


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Cambium Bio Business Description

Industry
Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.